MGMT promoter methylation in malignant gliomas

Targeted Oncology

Volumn 5, Issue 3, 2010, Pages 161-165

  Riemenschneider, Markus J ^a   Hegi, Monika E ^b   Reifenberger, Guido ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Glioma; Molecular diagnostics; O6 methylguanine DNA methyltransferase (MGMT); Prognosis; Promoter methylation

Indexed keywords

ISOCITRATE DEHYDROGENASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MOLECULAR MARKER; NITROSOUREA; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TEMOZOLOMIDE;

CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CHEMOSENSITIVITY; CHROMOSOME 10Q; CHROMOSOME 1P; CHROMOSOME 9Q; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CLINICAL TRIAL; CPG ISLAND; DNA METHYLATION; GENE INACTIVATION; GENE LOCATION; GENE MUTATION; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; PATIENT SELECTION; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; RADIOSENSITIVITY; REVIEW; TREATMENT OUTCOME;

ANIMALS; BRAIN NEOPLASMS; DNA METHYLATION; DNA, NEOPLASM; GLIOMA; HUMANS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PROMOTER REGIONS, GENETIC;

EID: 78049317939     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-010-0153-6     Document Type: Review

References (29)

1. SL Gerson 2004 MGMT: its role in cancer etiology and cancer therapeutics Nat Rev Cancer 4 4 296 307 1:CAS:528:DC%2BD2cXis1Gmt70%3D 10.1038/nrc1319 15057289
2. M Weller R Stupp G Reifenberger AA Brandes MJ van den Bent W Wick ME Hegi 2010 MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 6 1 39 51 1:CAS:528:DC%2BC3cXisV2gtA%3D%3D 10.1038/nrneurol.2009.197 19997073
3. SD Fouse JF Costello 2009 Epigenetics of neurological cancers Future Oncol 5 10 1615 1629 1:CAS:528:DC%2BD1MXhsFKnsrnN 10.2217/fon.09.132 20001799
4. RP Nagarajan JF Costello 2009 Epigenetic mechanisms in glioblastoma multiforme Semin Cancer Biol 19 3 188 197 1:CAS:528:DC%2BD1MXktV2isL0%3D 10.1016/j.semcancer.2009.02.005 19429483
5. S Everhard J Tost H El Abdalaoui E Criniere F Busato Y Marie IG Gut M Sanson K Mokhtari F Laigle-Donadey K Hoang-Xuan JY Delattre J Thillet 2009 Identification of regions correlating mgmt promoter methylation and gene expression in glioblastomas Neuro-Oncology 11 4 348 356 1:CAS:528: DC%2BD1MXhtV2qurzM 10.1215/15228517-2009-001 19224763
6. 6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer Oncogene 22 55 8835 8844 1:CAS:528:DC%2BD3sXpsVGhtrc%3D 14647440
7. JG Herman JR Graff S Myohanen BD Nelkin SB Baylin 1996 Methylation-specific PCR: a novel PCR assay for methylation status of cpg islands Proc Natl Acad Sci USA 93 18 9821 9826 1:CAS:528:DyaK28XlsFeht7Y%3D 10.1073/pnas.93.18.9821 8790415 (Pubitemid 26296693)
8. ME Hegi AC Diserens T Gorlia MF Hamou N de Tribolet M Weller JM Kros JA Hainfellner W Mason L Mariani JE Bromberg P Hau RO Mirimanoff JG Cairncross RC Janzer R Stupp 2005 MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 10 997 1003 1:CAS:528:DC%2BD2MXit1Wktro%3D 10.1056/NEJMoa043331 15758010 (Pubitemid 40349502)
9. 6-methylguanine-DNA methyltransferase gene promoter methylation in glioma J Mol Diagn 10 4 332 337 1:CAS:528:DC%2BD1cXpt1eitr8%3D 10.2353/jmoldx.2008.070169 18556773 (Pubitemid 352019119)
10. J Felsberg M Rapp S Loeser R Fimmers W Stummer M Goeppert HJ Steiger B Friedensdorf G Reifenberger MC Sabel 2009 Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients Clin Cancer Res 15 21 6683 6693 1:CAS:528:DC%2BD1MXhtlCjsrfP 10.1158/1078-0432.CCR-08-2801 19861461
11. 6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker Brain Pathol 18 4 520 532 1:CAS:528:DC%2BD1cXht1CjtLvM 18400046
12. M Esteller J Garcia-Foncillas E Andion SN Goodman OF Hidalgo V Vanaclocha SB Baylin JG Herman 2000 Inactivation of the DNA-repair gene mgmt and the clinical response of gliomas to alkylating agents N Engl J Med 343 19 1350 1354 1:CAS:528:DC%2BD3cXosFOltLg%3D 10.1056/NEJM200011093431901 11070098
13. U Herrlinger J Rieger D Koch S Loeser B Blaschke RD Kortmann JP Steinbach T Hundsberger W Wick R Meyermann TC Tan C Sommer M Bamberg G Reifenberger M Weller 2006 Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: Ukt-03 J Clin Oncol 24 27 4412 4417 10.1200/JCO.2006.06.9104 16983109 (Pubitemid 46630979)
14. R Stupp WP Mason MJ van den Bent M Weller B Fisher MJ Taphoorn K Belanger AA Brandes C Marosi U Bogdahn J Curschmann RC Janzer SK Ludwin T Gorlia A Allgeier D Lacombe JG Cairncross E Eisenhauer RO Mirimanoff 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 10 987 996 1:CAS:528:DC%2BD2MXit1Wksbk%3D 10.1056/NEJMoa043330 15758009 (Pubitemid 40349501)
15. M Weller J Felsberg C Hartmann H Berger JP Steinbach J Schramm M Westphal G Schackert M Simon JC Tonn O Heese D Krex G Nikkhah T Pietsch O Wiestler G Reifenberger A von Deimling M Loeffler 2009 Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the german glioma network J Clin Oncol 27 34 5743 5750 1:CAS:528:DC%2BC3cXhtVWisbg%3D 10.1200/JCO.2009.23. 0805 19805672
16. AL Rivera CE Pelloski MR Gilbert H Colman C De La Cruz EP Sulman BN Bekele KD Aldape 2010 MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma Neuro-Oncology 12 2 116 121 1:CAS:528:DC%2BC3cXotFKitb8%3D 20150378
17. W Wick C Hartmann C Engel M Stoffels J Felsberg F Stockhammer MC Sabel S Koeppen R Ketter R Meyermann M Rapp C Meisner RD Kortmann T Pietsch OD Wiestler U Ernemann M Bamberg G Reifenberger A von Deimling M Weller 2009 Noa-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide J Clin Oncol 27 35 5874 5880 1:CAS:528:DC%2BC3cXhtVWis7g%3D 10.1200/JCO.2009.23.6497 19901110
18. MJ van den Bent HJ Dubbink Y Marie AA Brandes MJ Taphoorn P Wesseling M Frenay CC Tijssen D Lacombe A Idbaih R van Marion JM Kros WN Dinjens T Gorlia M Sanson 2010 IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group Clin Cancer Res 16 5 1597 1604 10.1158/1078-0432.CCR-09-2902 20160062
19. 6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas Brain Pathol 13 2 176 184 1:CAS:528:DC%2BD3sXjsF2gurg%3D 10.1111/j.1750-3639.2003.tb00017.x 12744471
20. S Kesari D Schiff J Drappatz D LaFrankie L Doherty EA Macklin A Muzikansky S Santagata KL Ligon AD Norden A Ciampa J Bradshaw B Levy G Radakovic N Ramakrishna PM Black PY Wen 2009 Phase II study of protracted daily temozolomide for low-grade gliomas in adults Clin Cancer Res 15 1 330 337 1:CAS:528:DC%2BD1MXhs1eqsA%3D%3D 10.1158/1078-0432.CCR-08-0888 19118062
21. M Mollemann M Wolter J Felsberg VP Collins G Reifenberger 2005 Frequent promoter hypermethylation and low expression of the mgmt gene in oligodendroglial tumors Int J Cancer 113 3 379 385 10.1002/ijc.20575 15455350 (Pubitemid 40038704)
22. AA Brandes L Nicolardi A Tosoni M Gardiman P Iuzzolino C Ghimenton M Reni A Rotilio G Sotti M Ermani 2006 Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma Neuro-Oncology 8 3 253 260 1:CAS:528: DC%2BD28Xot1agtLo%3D 10.1215/15228517-2006-005 16723632 (Pubitemid 46542650)
23. MJ van den Bent HJ Dubbink M Sanson CR van der Lee-Haarloo M Hegi JW Jeuken A Ibdaih AA Brandes MJ Taphoorn M Frenay D Lacombe T Gorlia WN Dinjens JM Kros 2009 MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC brain tumor group study 26951 J Clin Oncol 27 35 5881 5886 10.1200/JCO.2009.24.1034 19901104
24. M Sanson Y Marie S Paris A Idbaih J Laffaire F Ducray S El Hallani B Boisselier K Mokhtari K Hoang-Xuan JY Delattre 2009 Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas J Clin Oncol 27 25 4150 4154 1:CAS:528:DC%2BD1MXhtF2jtLrP 10.1200/JCO.2009.21.9832 19636000
25. H Noushmehr DJ Weisenberger K Diefes HS Phillips K Pujara BP Berman F Pan CE Pelloski EP Sulman KP Bhat RG Verhaak KA Hoadley DN Hayes CM Perou HK Schmidt L Ding RK Wilson D Van Den Berg H Shen H Bengtsson P Neuvial LM Cope J Buckley JG Herman SB Baylin PW Laird K Aldape 2010 Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma Cancer Cell 17 5 510 522 1:CAS:528:DC%2BC3cXmslKqsr0%3D 10.1016/j.ccr.2010.03.017 20399149
26. HS Phillips S Kharbanda R Chen WF Forrest RH Soriano TD Wu A Misra JM Nigro H Colman L Soroceanu PM Williams Z Modrusan BG Feuerstein K Aldape 2006 Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis Cancer Cell 9 3 157 173 1:CAS:528:DC%2BD28XivFWjtL4%3D 10.1016/j.ccr.2006.02.019 16530701 (Pubitemid 43357943)
27. J Balss J Meyer W Mueller A Korshunov C Hartmann A von Deimling 2008 Analysis of the IDH1 codon 132 mutation in brain tumors Acta Neuropathol 116 6 597 602 1:CAS:528:DC%2BD1cXhtlyhsbfN 10.1007/s00401-008-0455-2 18985363
28. K Ichimura DM Pearson S Kocialkowski LM Backlund R Chan DT Jones VP Collins 2009 IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas Neuro-Oncology 11 4 341 347 1:CAS:528:DC%2BD1MXhtV2qur%2FF 10.1215/15228517-2009-025 19435942
29. S Nobusawa T Watanabe P Kleihues H Ohgaki 2009 IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas Clin Cancer Res 15 19 6002 6007 1:CAS:528:DC%2BD1MXhtF2ltbbL 10.1158/1078-0432.CCR-09-0715 19755387